Launch

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

By

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Five things for pharma marketers to know: Tuesday, May 9, 2017

Five things for pharma marketers to know: Tuesday, May 9, 2017

By

Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials

Five things for pharma marketers to know: Friday, January 20, 2017

Five things for pharma marketers to know: Friday, January 20, 2017

By

Pharma among top sponsors of Trump inauguration parties; AstraZeneca exec to replace GSK president of global pharmaceuticals; EpiPen rival to relaunch

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

By

Here's a look at 100 experimental therapies in late-stage clinical trials.

Five things for pharma marketers to know: Friday, October 28, 2016

Five things for pharma marketers to know: Friday, October 28, 2016

By

Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

By

The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.

Novartis ups marketing investment in Entresto, by $200 million

Novartis ups marketing investment in Entresto, by $200 million

By

One oft-cited challenge to Entresto's adoption has been prior authorization requirements.

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

By

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Five things for pharma marketers to know: Tuesday, April 5, 2016

Five things for pharma marketers to know: Tuesday, April 5, 2016

By

Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

BMS' Phelan: The digital drug launch is upon us

BMS' Phelan: The digital drug launch is upon us

By

From clinical trials to customer planning, digital can speed the biopharma product launch at each step, said Nancy Phelan, BMS head of commercial operations, at last week's MM&M Leadership Exchange.

Sandoz: Zarxio marketing to be similar to a branded-drug launch

Sandoz: Zarxio marketing to be similar to a branded-drug launch

By

Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.

Five things for pharma marketers to know: Tuesday, August 4

Five things for pharma marketers to know: Tuesday, August 4

By

Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014

Five things for pharma marketers to know: Wednesday, July 22

Five things for pharma marketers to know: Wednesday, July 22

By

Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed

Orchestrating Key Stakeholder Engagement for Launch Success

Orchestrating Key Stakeholder Engagement for Launch Success

The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.

19 US entries shortlisted at Lions Health

19 US entries shortlisted at Lions Health

By

The Lions Health award winners will be announced later Friday at an event in Cannes, France.

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Monday, May 4

Five things for pharma marketers to know: Monday, May 4

By

Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways

Five things for pharma marketers to know: Thursday, April 23

Five things for pharma marketers to know: Thursday, April 23

By

Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales

US drug spending shows reliance on specialty Rx

US drug spending shows reliance on specialty Rx

By

Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.

One giant leap for MannKind: Sanofi to market Afrezza

One giant leap for MannKind: Sanofi to market Afrezza

By

After weeks of speculation as to whether MannKind would find a marketing partner for its inhalable insulin, the drugmaker said today that Sanofi would acquire global licensing rights to the drug for $925 million.

Zohydro to get marketing overhaul

Zohydro to get marketing overhaul

By

The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.

Belviq scripts jump on DTC, rep push

Belviq scripts jump on DTC, rep push

By

Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

By

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

By

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

Sanofi seeks to revive Kynamro launch

Sanofi seeks to revive Kynamro launch

By

Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.

Sovaldi launch trounces Incivek's

Prescription data shows Gilead's Sovaldi is winning prescriptions at a faster rate than Vertex's Incivek did at launch.

Biogen CEO cautions on Tecfidera EU launch

Biogen CEO cautions on Tecfidera EU launch

By

The MS pill saw rapid uptake in the US last year, but its overseas launch won't be as quick, CEO George Scangos conceded this week at an analyst conference.

As HIV meds mature, Gilead preps for HCV launch

As HIV meds mature, Gilead preps for HCV launch

By

A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.

Tecfidera sales soar, cannibalize older med

Tecfidera sales soar, cannibalize older med

By

Based on its first three months on market, Tecfidera is one launch that's living up to its hype.

Opinion

How to Shatter the Glass Ceiling

How Pharma Can Benefit from the Transformation of Pharmacy

Newsletters

Live at MM&M Transforming Healthcare

Pharma faces its 'oh, shit' moment

In his keynote address at the MM&M Transforming Healthcare conference, Dr. Gautam Gulati says the industry is being outpaced by its innovation.

Merck, Takeda execs: Is AI the new bad app?

One executive referred to AI as a "black box" and as the "Tower of Babel."

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

Admetsys wins the 2017 MM&M Startup Showdown

The artificial pancreas can provide value to the health system.

Top 40 Healthcare Transformers

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts

For the first time MM&M honors a group of 10 agency execs.